Logo image
When Symptoms Persist: Clozapine Augmentation Strategies
Journal article   Peer reviewed

When Symptoms Persist: Clozapine Augmentation Strategies

Peter Buckley, Alexander Miller, Jerry Olsen, David Garver, Del D Miller and John Csernansky
Schizophrenia bulletin, Vol.27(4), pp.615-628
2001
DOI: 10.1093/oxfordjournals.schbul.a006901
PMID: 11824488

View Online

Abstract

Recent data and clinical experience confirm that, in spite of superior efficacy for treatment-refractory schizophrenia, a substantial proportion of patients receiving clozapine will continue to experience disabling symptoms. Optimizing clozapine monotherapy is the first step in the management of "clozapine nonresponders." Described here is a synthesis of the available literature on the range and efficacy of clozapine augmentation strategies that may be used when monotherapy fails. Treatment options include adjunctive antipsychotic medications, mood stabilizers, selective serotonin reuptake inhibitors, glycinergic agents, and electroconvulsive therapy. The evidence favoring one augmentation strategy over another is lacking; overall, adjunctive therapy is associated with only modest clinical improvement. Moreover, case series and open-labeled clinical trials dominate the extant literature, and there is a dearth of double-blind trials comparing these augmentation agents. Current systematic efforts to enhance the treatment of these patients with adjunctive therapies are worthy of being studied in carefully conducted clinical trials.
Schizophrenia clozapine antipsychotic response treatment refractory augmentation

Details

Logo image